-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $147

Benzinga·11/05/2026 16:12:04
Listen to the news
Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $147.